Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
135
resultados
Última actualización
01/09/2024 [07:12:00]
Resultados 25 a 50 de 135
Resumen de: US2024247315A1
A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.
Resumen de: US2024245087A1
The use of fermented camel milk with a honey propolis engineered probiotic for treating bowel disorders (BD). The honey propolis is used as a synergistic supplement to engineer the probiotic bacterium, Enterococcus faecium (EF), at a defined bacterial load, propolis concentration, and incubation period. The engineered EF is included with fermented camel's milk, which is then administered orally to those suffering from a BD. Effective treatment can be observed both through reduced adverse effects, as well as reduced levels of immune-modulatory markers such as TNF α, VEGF-1, IL-1β, IFN-γ IFN T γ-6 and TGF-β.
Resumen de: US2023089727A1
The present invention generally pertains to methods of characterizing at least one protein of interest in a biological sample. In particular, the present invention pertains to the use of automated iterative tandem mass spectrometry (AIMS) to identify, quantify and characterize at least one protein of interest and/or biomarker from a biological sample such as plasma.
Resumen de: US2024238340A1
The present disclosure includes compositions and methods for treating gastrointestinal inflammatory disease and/or cancers. In certain aspects, the disclosure includes an isolated cell comprising a nucleic acid vector comprising a gene encoding the transcription factor ZBTB20 which is operably linked to a promoter.
Resumen de: US2024241135A1
The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1α (REGIA), each antibody in the antibody combination can specifically bind to REGIA with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REGIA. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REGIA-related diseases.
Resumen de: US2024230666A1
The present invention relates to methods for detecting disease-relevant microbial colonization of the gut mucosal surface (proinflammatory mucosal dysbiosis) prior to onset of overt inflammation by measuring a level of interleukin 17C (IL17C) and other microinflammation markers in a biological sample from a subject and treating and/or preventing intestinal inflammation if these markers are elevated.
Resumen de: US2024230640A1
The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.
Resumen de: WO2024148218A2
Described herein are methods of treating inflammatory diseases or conditions such as inflammatory bowel diseases including Crohn's disease and ulcerative colitis, the methods comprising administering a TL1A inhibitor and a TNF inhibitor contemporaneously for the duration of treatment or contemporaneously during an induction phase of treatment followed by maintenance of response with the TL1A inhibitor alone or TNF inhibitor alone.
Resumen de: US2024218334A1
Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.
Resumen de: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Resumen de: US2024209103A1
A Provided herein are methods and compositions for patient selection and therapies targeting TL1A. In particular, provided is a method of treating moderate to severely active Crohn's disease (CD) or ulcerative colitis (UC) in a subject, the method comprising: administering a therapeutically effective amount of an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression to a subject with moderately to severely active CD or UC that has been determined have a polygenetic risk score (PRS) in the 75th percentile, which is indicative of high fold-change of TL1A expression relative to a cut-off fold-change value. Calculating a PRS comprises providing genomic data comprising one or more genotypes (e.g. rs11221332, rs7134599, rs6062496, rs4246905, rs7468800, rs1569328, rs2284553, rs6062504, and rs7556897) of the subject associated with high TL1A fold-change relative to an index or a control.
Resumen de: CN117286238A
Methods of predicting a high or low probability of developing inflammatory bowel disease (IBD) in a subject, and methods of diagnosing inflammatory bowel disease (IBD) in a subject are described. The invention further provides methods of identifying genes/genetic loci associated with disease conditions such as IBD, CD and/or UC.
Resumen de: CN118240070A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Resumen de: US2022162703A1
The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-γ. The invention further provides a process for patient identification and/or stratification.
Resumen de: CN118229600A
The invention relates to the technical field of medical image processing, in particular to an ulcerative colitis related tumor virtual staining method under an enteroscope, which comprises the following steps: acquiring an enteroscope white light image and a corresponding indigo carmine staining image; performing random noise adding processing on the indigo carmine dyeing image, splicing the noise-added image and the corresponding enteroscope white light image as input data, and inputting the input data into a U-Net model with time steps; on the basis of a back propagation process for generating a diffusion model, splicing a random noise image and an enteroscope white light image to be virtually dyed, and inputting the spliced image into the trained U-Net model for estimation; and splitting the final estimation result by operation opposite to the splicing method to obtain an indigo carmine dyeing prediction result. According to the virtual staining method for the ulcerative colitis related tumors under the enteroscope, a better display effect can be obtained, and the professional and experience requirements on endoscopic doctors during screening and diagnosis of UCAN are reduced.
Resumen de: AU2022289038A1
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
Resumen de: US2024199700A1
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Resumen de: WO2024127406A1
The invention relates to system and methods for predicting and/or diagnosing of IBD from ultrasound images according to one or more of diagnostic signs.
Resumen de: CN118207209A
The invention belongs to the technical field of hypochlorous acid (HClO) detection, and particularly relates to an MHDNA probe and application thereof in hypochlorous acid imaging of ulcerative colitis. The MHDNA probe is formed by assembling Hpa with a sequence as shown in SEQ ID NO.5 and Hpb with a sequence as shown in SEQ ID NO.6 on a tetravalent cross-shaped DNA structure composed of M1, M2, M3 and M4 as shown in SEQ ID NO.1-4 through base complementary pairing; the basic group T at the 22nd site of the M3 is modified with thiophosphate; a fluorescence reporter group and a fluorescence quenching group are modified on the Hpa. The MHDNA probe disclosed by the invention is combined with a catalytic hairpin assembly (CHA) reaction, so that HClO can be sensitively and specifically detected, and in-vivo imaging and disease diagnosis of inflammatory bowel diseases are realized.
Resumen de: CN118184817A
The invention discloses preparation and application of laminarin with immunoregulatory activity. According to the acetylated laminarin, the expression of proinflammatory factors is reduced, the expression of anti-inflammatory factors is increased, and the acetylated laminarin has an obvious positive effect on the balance of proinflammatory-anti-inflammatory factors in mice with ulcerative colitis. The acetylated laminarin has a regulating effect on macrophage markers (the ratio of CD68 to CD163) in a mouse with ulcerative colitis, and can be used for alleviating the symptoms of the UC mouse by possibly influencing the transformation of M1 type macrophages in intestinal tracts into M2 type macrophages and increasing the proportion of M2/M1 so as to regulate the generation of pro-anti-inflammatory factors. Meanwhile, the invention provides a preparation method of the acetylated laminarin, and the preparation method is simple and medical, does not need complex chemical synthesis reaction, and is single in reaction product, high in yield and suitable for industrial large-scale production.
Resumen de: US2024189458A1
The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.
Resumen de: AU2022321666A1
A method for detecting gastrointestinal permeability in a subject comprises administering a solution comprising lactulose and galactose to the subject. A sample of blood is taken from the subject after administering the solution. A ratio of the concentration of lactulose to the concentration of galactose in the blood sample is an indicator of gastrointestinal permeability.
Resumen de: CN118165073A
The invention discloses an FAP inhibitor and a preparation method and application thereof.The general formula of the FAP inhibitor is shown in the formula I. The novel FAP inhibitor can be combined with corresponding radioactive elements to be used for diagnosis and treatment of FAP positive related diseases, and compared with traditional FAPI radiopharmaceuticals, the FAP inhibitor has the advantages that the FAP inhibitor can be applied to diagnosis and treatment of FAP positive related diseases; the novel FAP inhibitor is higher in uptake rate at a focus part, higher in target-to-non-target contrast ratio and free of obvious toxic and side effects; the compound can also be used for treating and diagnosing diseases such as tumors (pancreatic cancer, breast cancer, ovarian cancer, lung cancer, colorectal cancer and gastric cancer), myocardial infarction, scar formation, osteoporosis, liver, kidney and pulmonary fibrosis, chronic inflammation and destructive processes (rheumatoid arthritis, Crohn's disease, atherosclerotic plaque and immune globulin related diseases) and the like. # imgabs0 #
Resumen de: CN118150754A
The invention provides a quality evaluation method of a traditional Chinese medicine compound preparation for treating ulcerative colitis. The raw materials of the traditional Chinese medicine compound preparation comprise pomegranate seeds, nutgall, purslane and semen plantaginis, and the quality evaluation method comprises the following steps: 1) carrying out qualitative identification on the raw materials in the traditional Chinese medicine compound preparation by adopting a thin layer chromatography; 2) performing quantitative analysis on the quality control components in the traditional Chinese medicine compound preparation according to high performance liquid chromatography; 3) establishing a fingerprint spectrum analysis method of the traditional Chinese medicine compound preparation according to high performance liquid chromatography; and 4) evaluating the quality of the traditional Chinese medicine compound preparation by combining the packing volume difference, moisture, disintegration time limit and microbial limit of the traditional Chinese medicine compound preparation, the qualitative identification result obtained in the step 1), the quantitative analysis result obtained in the step 2) and the fingerprint spectrum result obtained in the step 3). The method can solve the problem of lack of a comprehensive quality evaluation method for the traditional Chinese medicine compound preparation in the prior art, and is suitable for the field of medicine quality control
Nº publicación: CN118147039A 07/06/2024
Solicitante:
HEFEI UNIV OF TECHNOLOGY
\u5408\u80A5\u5DE5\u4E1A\u5927\u5B66
Resumen de: CN118147039A
The invention belongs to the technical field of cell biology, and particularly relates to a preparation and identification method and application of a small intestine organoid and an exosome of the small intestine organoid, and the preparation and identification method comprises the following steps: S1, taking small intestine tissues of mice, digesting and dissociating small intestine stem cells, and culturing the small intestine stem cells into the small intestine organoid; s2, using hematoxylin eosin staining to observe the tissue structure of small intestine organoids of the mouse; and S3, determining the marker gene level of each cell of the small intestine organoids of the mouse by adopting real-time fluorescent quantitative PCR (Polymerase Chain Reaction). The preparation method provided by the invention can realize efficient separation and purification of the small intestine organoid exosome, is beneficial to research on an intestinal injury repair mechanism in the inflammatory bowel disease, and provides a more targeted treatment mode and selection for the disease; the method has great significance in regenerative medicine related fields and development of intestinal disease diagnosis and personalized precise treatment.
BOPI
Sede Electrónica
